결장암에서 5-Fluorouracil-based 보조항암화학요법의 치료반응 예측인자로써 점액성 선암의 의의 = Mucinous Histology as a Predictive Marker of 5-Fluorouracil-based Adjuvant Chemotherapy for Colon Cancer

다국어 초록 (Multilingual Abstract)

Purpose: The aim of this study was to evaluate the value of mucinous histology as a predictive marker of 5-Fluorouracil (FU)-
based adjuvant chemotherapy in stage II, III colon cancer.
Methods: Between January 1995 and December 2004, 987 patients who underwent curative resections for stage II, III
sporadic colon cancer were classified into two groups, a mucinous carcinoma (MC) group and a non-mucinous carcinoma
(NMC) group, based on the histology of the primary tumor. The differences in their clinicopathological characteristics and
the prognostic impact of 5-FU-based adjuvant chemotherapy for various tumor histologies were analyzed.
Results: Of the 987 patients, MCs accounted for 6.8% (68 patients). MCs were more frequently located in the Rt. Colon (P<
0.001) and were more frequently seen in young patients (less than 40 yr old) (P=0.028). The 5-yr survival rates between MC
and NMC did not show any statistically significant difference. Patients, including both MC and NMC patients, who received
5-FU-based chemotherapy, revealed a better overall survival rate than patients with no adjuvant chemotherapy. In the multivariate
analysis for the prognosis in NMC patients, 5-FU-based adjuvant chemotherapy, initial negative nodal status, and
preoperative CEA <5 ng/mL were statistically significant prognostic factors (P values: <0.001, <0.001, and <0.001, respectively).
In contrast, there was no statistically independent significance of 5-FU-based adjuvant chemotherapy in MC patients.
Conclusion: In stage II and stage III sporadic colon cancer patients, response to 5-FU-based adjuvant chemotherapy in
MC patients might be poor than it is in NMC patients.

다국어 초록 (Multilingual Abstract)

Purpose: The aim of this study was to evaluate the value of mucinous histology as a predictive marker of 5-Fluorouracil (FU)-
based adjuvant chemotherapy in stage II, III colon cancer.
Methods: Between January 1995 and December 2004, 987 patients who underwent curative resections for stage II, III
sporadic colon cancer were classified into two groups, a mucinous carcinoma (MC) group and a non-mucinous carcinoma
(NMC) group, based on the histology of the primary tumor. The differences in their clinicopathological characteristics and
the prognostic impact of 5-FU-based adjuvant chemotherapy for various tumor histologies were analyzed.
Results: Of the 987 patients, MCs accounted for 6.8% (68 patients). MCs were more frequently located in the Rt. Colon (P<
0.001) and were more frequently seen in young patients (less than 40 yr old) (P=0.028). The 5-yr survival rates between MC
and NMC did not show any statistically significant difference. Patients, including both MC and NMC patients, who received
5-FU-based chemotherapy, revealed a better overall survival rate than patients with no adjuvant chemotherapy. In the multivariate
analysis for the prognosis in NMC patients, 5-FU-based adjuvant chemotherapy, initial negative nodal status, and
preoperative CEA <5 ng/mL were statistically significant prognostic factors (P values: <0.001, <0.001, and <0.001, respectively).
In contrast, there was no statistically independent significance of 5-FU-based adjuvant chemotherapy in MC patients.
Conclusion: In stage II and stage III sporadic colon cancer patients, response to 5-FU-based adjuvant chemotherapy in
MC patients might be poor than it is in NMC patients.

참고문헌 (Reference)

1 유윤식, "특징적 임상 양상 및 예후를 가지는 결장 및 직장의 점액성 선암" 대한대장항문학회 19 (19): 379-385, 2003

2 이강영, "대장 직장에서 점액성 선암의 임상적 특징" 대한외과학회 64 (64): 140-143, 2003

3 Ribic CM, "Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer" 349 : 247-257, 2003

4 Jover R, "The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status" 45 : 365-373, 2009

5 Jass J, "The World Health Organization’s histologic classification of gastrointestinal tumors: a commentary on the second edition" 66 : 2162-2167, 1990

6 Kanemitsu Y, "Survival after curative resection for mucinous adenocarcinoma of the colorectum" 46 : 160-167, 2003

7 Desch CE, "Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology" 17 : 1312-, 1999

8 Uen YH, "Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection" 246 : 1040-1046, 2007

9 Galandiuk S, "Patterns of recurrence after curative resection of carcinoma of the colon and rectum" 174 : 27-32, 1992

10 Negri FV, "Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer" 16 : 1305-1310, 2005

11 Kazama Y, "Mucinous carcinomas of the colon and rectum show higher rates of microsatellite instability and lower rates of chromosomal instability: a study matched for T classification and tumor location" 103 : 2023-2029, 2005

12 Sundblad AS, "Mucinous carcinomas of the colon and rectum and their relation to polyps" 50 : 2504-2509, 1982

13 Green JB, "Mucinous carcinoma--just another colon cancer?" 36 : 49-54, 1993

14 Watanabe T, "Molecular predictors of survival after adjuvant chemotherapy for colon cancer" 344 : 1196-1206, 2001

15 Carethers JM, "Mismatch repair proficiency and in vitro response to 5-fluorouracil" 117 : 123-131, 1999

16 Messerini L, "Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico-pathological variables" 182 : 380-384, 1997

17 Benatti P, "Microsatellite instability and colorectal cancer prognosis" 11 : 8332-8340, 2005

18 Moertel CG, "Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma" 322 : 352-358, 1990

19 Moertel CG, "Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report" 122 : 321-326, 1995

20 King-Yin Lam A, "Colorectal mucinous adenocarcinoma: the clinicopathologic features and significance of p16 and p53 expression" 46 : 1275-1283, 2006

21 O’Connell JB, "Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging" 96 : 1420-1425, 2004

22 Nozoe T, "Clinicopathological characteristics of mucinous carcinoma of the colon and rectum" 75 : 103-107, 2000

23 Greene FL, "American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed" Springer 2002

24 Kang H, "A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum" 48 : 1161-1168, 2005